Skip to main content
Biology of Reproduction logoLink to Biology of Reproduction
. 2022 Nov 8;108(1):107–120. doi: 10.1093/biolre/ioac191

Neurotensin expression, regulation, and function during the ovulatory period in the mouse ovary

Ketan Shrestha 1, Linah Al-Alem 2, Priscilla Garcia 3, Michelle A A Wynn 4, Patrick R Hannon 5, Misung Jo 6, Jenny Drnevich 7, Diane M Duffy 8, Thomas E Curry Jr 9,
PMCID: PMC9843676  PMID: 36345168

Abstract

The luteinizing hormone (LH) surge induces paracrine mediators within the ovarian follicle that promote ovulation. The present study explores neurotensin (NTS), a neuropeptide, as a potential ovulatory mediator in the mouse ovary. Ovaries and granulosa cells (GCs) were collected from immature 23-day-old pregnant mare serum gonadotropin primed mice before (0 h) and after administration of human chorionic gonadotropin (hCG; an LH analog) across the periovulatory period (4, 8, 12, and 24 h). In response to hCG, Nts expression rapidly increased 250-fold at 4 h, remained elevated until 8 h, and decreased until 24 h. Expression of Nts receptors for Ntsr1 remained unchanged across the periovulatory period, Ntsr2 was undetectable, whereas Sort1 expression (also called Ntsr3) gradually decreased in both the ovary and GCs after hCG administration. To better understand Nts regulation, inhibitors of the LH/CG signaling pathways were utilized. Our data revealed that hCG regulated Nts expression through the protein kinase A (PKA) and p38 mitogen-activated protein kinase (p38MAPK) signaling pathways. Additionally, epidermal-like-growth factor (EGF) receptor signaling also mediated Nts induction in GCs. To elucidate the role of NTS in the ovulatory process, we used a Nts silencing approach (si-Nts) followed by RNA-sequencing (RNA-seq). RNA-seq analysis of GCs collected after hCG with or without si-Nts identified and qPCR confirmed Ell2, Rsad2, Vps37a, and Smtnl2 as genes downstream of Nts. In summary, these findings demonstrate that hCG induces Nts and that Nts expression is mediated by PKA, p38MAPK, and EGF receptor signaling pathways. Additionally, NTS regulates several novel genes that could potentially impact the ovulatory process.

Keywords: neurotensin, ovulation, granulosa cells, siRNA, silencing, RNAseq


Nts expression increased 250-fold 4 h after hCG in mouse ovaries and is regulated through classical hCG signaling pathways. Using siRNA followed by RNAseq, Ell2, Rsad2, Vps37a, and Smtnl2 were identified as NTS downstream targets in granulosa cells.

Graphical abstract

graphic file with name ioac191ga.jpg

Introduction

The midcycle surge of luteinizing hormone (LH) triggers the ovulatory cascade of events within the ovarian follicle leading to oocyte expulsion followed by the formation of the corpus luteum. This initiation of the ovulatory process by the LH surge is accomplished by the production and regulation of paracrine mediators from the follicular cells that express LH receptors [1]. Our recent studies have revealed neurotensin (NTS) as one of the essential paracrine mediators in the ovulatory follicle [2, 3].

NTS is a small 13-amino-acid neuropeptide that was first characterized as a neurotransmitter in neuronal cells. However, NTS has been found throughout the body, such as in the cardiovascular system, the gastrointestinal tract, the endocrine system, and the reproductive system [4–6]. In the ovary, studies have reported that the ovulatory LH surge increases NTS expression in granulosa cells of humans, non-human primates, rats, and cows [2, 3, 7–9]. A recent study in non-human primates has revealed that injecting a NTS-neutralizing antibody into preovulatory macaque follicles yielded ovaries containing entrapped oocytes within unruptured, hemorrhagic follicles [3] demonstrating a key role for NTS in ovulation. However, the potential mechanisms of NTS action in the ovulatory process are unknown.

NTS carries out its function via its three well-characterized receptors: NTSR1, NTSR2, and SORT1 (also known as sortillin or NTSR3). NTSR1 and NTSR2 belong to the family of classical G protein-coupled, seven transmembrane spanning domain receptors whereas SORT1 is a single transmembrane receptor, non-coupled to G-proteins, which belongs to the Vps10p containing domain receptor family [10, 11]. Depending upon the target cells, NTS action is dependent on the specific receptor to which it binds, the abundance of each receptor, the specific tissue location of the NTS receptor, and the interaction between the NTS receptors [12–14]. NTS has been reported to promote cell migration [13, 15], extracellular matrix remodeling [16], and cell cycle/apoptosis [17, 18], all of which are also key cell functions during ovulation and transformation of the follicle into the corpus luteum [19].

Although there is a body of literature on NTS, little is known about the specific actions of NTS in the ovulatory process. Particularly, the role of NTS as a paracrine mediator has not been explored in the periovulatory follicular cells. In the present study, we utilized pregnant mare serum gonadotropin (PMSG)/human chorionic gonadotropin (hCG)-primed immature mouse models to first characterize the expression of NTS and its receptors in the ovary and then investigate the function of NTS during the ovulatory process using an RNA-silencing (RNA-seq) approach, followed by RNA-seq.

Materials and methods

Media and reagents

Unless otherwise specified, all chemicals and reagents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Culture media and TaqMan Gene Expression Master Mix were purchased from Invitrogen Life Technologies (Carlsbad, CA).

In vivo mouse ovary collection

All animal procedures for these experiments were approved by the University of Kentucky IACUC. Immature female C57BL/6 mice (Charles River Laboratories, Wilmington, MA) at postnatal day (PND) 23–24 were subcutaneously injected with PMSG (5 IU) to stimulate the development of multiple follicles. After 48 h, some animals were euthanized to serve as the control group (0 h). The remaining mice were subcutaneously injected with hCG (2.5 IU) to induce the ovulatory cascade. These animals were euthanized at set times across the periovulatory period (4, 8, 12, and 24 h post-hCG administration). Mice ovulate shortly following the 12 h time point. Whole intact ovaries were collected at the designated time points and stored at –80 °C for later analysis or punctured to collect granulosa cells [20].

Mouse granulosa cell culture

Immature 23–24 PND mice were subcutaneously injected with PMSG (5 IU) as described previously. After 48 h, the animals were euthanized and ovaries were isolated. Briefly, granulosa cells were isolated by follicular puncture, pooled, filtered, pelleted by centrifugation, and resuspended in Opti-MEM medium supplemented with 0.05 mg/mL of gentamycin and 1x ITS (insulin, transferrin, and selenium) as routinely performed in our laboratory [20]. Cells were plated in 12-well dish (250,000 cells/well) and then treated immediately with or without hCG (1 IU/mL), cultured at 37 °C in a humidified atmosphere of 5% CO2 and collected at the time of culture or after 4, 8, 12, or 24 h of treatment.

To determine the pathways regulating NTS expression, the cells were pre-treated with the inhibitors of the following LH-activated signaling pathways for 1 h: H89 (PKA inhibitor, 10 μM), GF (GF109203x; PKC inhibitor 1 μM), LY (LY294002; PI3K inhibitor 25 μM), PD (PD98059; MEK1/2 inhibitor, 20 μM) or SB (SB203580; p38 MAPK inhibitor 20 μM). Cells were then treated with or without hCG for 4 h in the absence or presence of above-mentioned inhibitors. In parallel, inhibitors of LH-induced paracrine factors were also pre-incubated for 1 h: the EGF receptor inhibitor (AG1478;1 μM), progesterone receptor antagonist (RU486; 1 μM), prostaglandin synthase 2 inhibitor (NS398; 1 μM). These doses have previously been shown to be effective inhibitors of their respective targets [2, 21]. Then, cells were treated with or without hCG in the absence or presence of the above-mentioned inhibitors for 4 h. At the end of culture, cells were collected and mRNA was isolated as described below.

Nts silencing by small interfering RNA

Mouse granulosa cells were isolated from ovaries of PMSG-primed mice. Cells (180,000 cells/well in a 12-well dish) were seeded and transfected immediately before cells could adhere to the wells using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Cells were transfected in suspension with 5 nmol/L of a small interfering RNA construct targeting Nts (si-Nts; assay s84990; Thermo Fisher Scientific), or with scrambled siRNA (the negative control; si-NC, assay 4390844; Thermo Fisher Scientific). Transfected cells were incubated for 3 h before stimulating with hCG (1 IU/mL), cultured for additional 4 and 12 h, and then harvested.

RNA isolation and sequencing

Total RNA was extracted from granulosa cells transfected with or without si-Nts at 4 and 12 h after hCG using RNeasy Mini Kit (Qiagen, Valencia, CA) with DNase (Qiagen) as per the manufacturer’s instructions as routinely performed in our laboratory [21]. The quality of total RNA was assessed by Bioanalyzer RNA Nano chip kit (Agilent, Santa Clara, CA). RNA-seq and analysis were performed at the Roy J. Carver Biotechnology Center, University of Illinois. The RNAseq libraries were prepared with Illumina’s “TruSeq Stranded mRNAseq Sample Prep kit” (Illumina). The libraries were pooled, quantitated by qPCR, and sequenced on two SP lanes for 151 cycles from both ends of the fragments on a NovaSeq 6000. Salmon (v1.4.0) [22] was used to quasi-map reads to the National Center for Biotechnology Information’s Mus musculus Annotation Release 109 transcriptome using GRCm39 genome as the decoy sequence and options --seqBias --gcBias --numBootstraps = 30 -validateMappings. Gene-level counts were then estimated based on transcript-level counts using the “bias corrected counts without an offset” method from the tximport package [23] in R (v4.1.0). The detection threshold was set at 0.5 cpm (counts per million) in at least four samples, which resulted in 24,891 genes being filtered out, leaving 14,362 genes to be analyzed for differential expression. After filtering, the trimmed mean of M (TMM) normalization was performed and normalized log2-based cpm values (logCPM) were calculated using edgeR [24]. Differential gene expression analysis was performed using the limma-trend method [25] using a model of Group + Date. Date was considered for sample batch effect. A global false discovery rate (FDR) correction was done across all contrasts at once so that the same raw P-value in any contrast ends up with the same FDR P-value. Threshold of 0.05 was setup for global FDR correction.

Quantitative PCR analysis

Total RNA was isolated from in vivo or in vitro mice samples using a RNeasy Mini kit from Qiagen according to the manufacturer’s protocol as routinely performed in our laboratory [21]. Total RNA (100 or 200 ng) was reverse transcribed according to the manufacturer’s protocol using the iScript RT kit from Bio-Rad Laboratories, Inc. All samples were diluted to 1.67 ng/μL for quantitative real-time polymerase chain reactions (qPCR). The AriaMx Real-Time PCR system and the comprehensive data analysis software were used in this study. Data were generated using the TaqMan Gene Expression Master Mix (Invitrogen Life Technologies, Inc.) reagents. The expression was analyzed by using 20XTaqMan Gene Expression Assay primers (Table 1) from Applied Biosystems (Foster City, CA). The thermal cycling steps: 2 min at 50 °C to permit AmpErase uracil-N-glycosylase optimal activity, a denaturation step for 10 min at 95 °C, 15 s at 95 °C and 1 min at 60 °C for 50 cycles, followed by 1 min at 95 °C, 30 s at 58 °C, and 30 s at 95 °C for ramp dissociation. The relative amount of mRNA in each sample was calculated following the 2-ΔΔCT method and normalized to ribosomal protein L32 (Rpl32).

Table 1.

TaqMan primers used for quantitative PCR

Genes Assay ID Accession no.
Rpl32 Mm02528467_g1 NM_172086.2
Nts Mm00481140_m1 NM_024435.2
Ntsr1 Mm00444459_m1 NM_018766.2
Sort1 Mm00490905_m1 NM_001271599.1
Ptgs2 Mm00478374_m1 NM_011198.4
Pgr Mm00435628_m1 NM_008829.2
Ell2 Mm01352835_m1 NM_138953.2
Rsad2 Mm01287122_m1 NM_021384.4
Vps37a Mm00712884_m1 NM_033560.3

Western blot analysis

From mouse ovarian tissues, whole-cell extracts were isolated by adding cell lysis buffer (50 mM Tris; pH 8.0, 150 mM NaCl, 1% Triton X-100, and 1 mM EDTA). Protein quantification were done using Pierce detergent compatible Bradford assay reagent (Thermo Fisher Scientific, IL) and then sample buffer (x2) was added and denatured at 95°C for 5 min. Proteins (20 μg) were separated by 12.0% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred to nitrocellulose membranes. Membranes were blocked for 1 h at room temperature in TBST (25 mM Tris, 137 mM NaCl, 2.7 mM KCl, and 0.05% TWEEN-20) containing 5% low-fat milk and then incubated overnight at 4 °C with 1:1000 mouse anti-NTSR1 (Santa Cruz Biotechnology Cat# sc-374492, RRID:AB_10989085 [26]), 1:1000 mouse anti-SORT1 (Abcam Cat# ab16640, RRID:AB_2192606 [27]), and 1:2000 rabbit anti-BACT (Cell Signaling Technology Cat# 4970, RRID:AB_2223172 [28]) in 1% low-fat milk. The membranes were incubated with the respective secondary horseradish peroxidase–conjugated antibody for 1 h. A chemiluminescent signal was generated with the Amersham ECL Prime Western blotting detection reagent and the signal was captured using ChemiDoc (Bio-Rad Laboratories, CA).

Progesterone (P4) assay

The concentration of progesterone was measured using an Immulite kit (Diagnostic Products, CA) as described previously [19, 20]. Assay sensitivity for the Immulite was 0.02 ng/mL. The intra- and inter-assay coefficients of variation were 7 and 12%, respectively.

MTS assay

The cell metabolic activity was measured using the CellTiter 96 Aqueous One Solution MTS assay according to the manufacturer’s protocol (Promega). In a 48-well dish, 50,000 cells were plated and immediately transfected with scrambled siRNA (si-NC) or siRNA targeting Nts (si-Nts) for 3 h. Then, cells were treated with or without hCG (1 IU/mL) for additional 24 h. At the end of culture, 40 μL of MTS reagent was pipetted into each well and then further incubated for an additional 2 h. The absorbance was measured at 490 nm in an Infinite F200 plate reader (Tecan) to determine the formazan concentration.

Statistical analysis

Data are presented as means ± SEM. Statistical analyses were performed using one-way analysis of variance (ANOVA) to test differences among treatments as appropriate. Tukey’s post-hoc test was performed in order to identify significant differences among treatments. Means were compared with P ≤ 0.05 considered significant. Statistical analysis was performed using GraphPad Prism (GraphPad 9, La Jolla, CA).

RESULTS

hCG increases Nts mRNA expression in vivo and in vitro

Expression of Nts was examined in whole ovaries collected across the periovulatory period. The expression of Nts increased approximately 250-fold at 4 h after hCG which remained elevated until 8 h post-hCG, then the mRNA levels gradually declined back to baseline at 24 h after hCG (P > 0.05; Figure 1A). Next, we examined the in vivo expression of Nts in mouse granulosa cells. Similar to our findings from the whole ovary, Nts expression displayed a similar pattern in mouse granulosa cells, with an induction of Nts by hCG at 4 h and levels declining throughout the late periovulatory period (Figure 1B). To determine the granulosa cell contribution of Nts expression observed in whole ovaries, Nts expression was directly compared in whole ovaries and granulosa cells at 4 h after hCG. The Nts mRNA levels in granulosa cells were approximately 8-fold higher at 4 h after hCG than in whole ovaries. The lowest level of detection for Nts expression was 35 Ct values in whole ovaries and in vivo granulosa cells, which was within the linear range of the qPCR assay. We also found a similar pattern of Nts induction by hCG treatment in cultured granulosa cells. As shown in Figure 1C, hCG upregulated Nts at 4 h and the induction remained elevated at 8 h, confirming that the induction of Nts mRNA levels in cultured granulosa cells is similar to that in granulosa cells of the periovulatory follicle in vivo.

Figure 1.

Figure 1

Expression of Nts across the periovulatory period. Expression of Nts mRNA levels in mouse ovaries (A), in mouse granulosa cells in vivo (B), and cultured mouse granulosa cells in vitro (C) following hCG administration. Results are the means ± SEM. N = 4. Bars that do not share a letter designation are significantly different (P < 0.05).

Expression of Nts receptors across the periovulatory period

The expression of the three different known NTS receptors designated as Ntsr1, Ntsr2, and Sort1 was determined in mouse ovaries and granulosa cells in order to better understand how NTS conveys its function in the ovary. In intact ovaries, expression of Ntsr1 did not change with hCG treatment (Figure 2A). Ntsr2 had cycle threshold values above 40 cycles, indicating low levels of expression. Ntsr2 expression did not change with hCG treatment (data not shown). As shown in Figure 2B, Sort1 expression decreased over the ovulatory period with the lowest levels at 24 h. When confirming the protein levels of NTSR1 and SORT1, we found that the protein levels were unchanged across the periovulatory period (Figure 2C and D, respectively). Similarly, in granulosa cells collected across the periovulatory period, expression of Ntsr1 (Figure 2E) did not change, whereas Ntsr2 was not detectable (data not shown). Also, Sort1 expression in mouse granulosa cells in vivo tended to decline but was not statistically different over the periovulatory period (Figure 2F).

Figure 2.

Figure 2

Expression of Nts receptors across the periovulatory period. The expression of Ntsr1 (A) and Sort1 (B) in mouse ovaries collected after hCG is shown. Western blots illustrate representative protein bands of NTSR1 (C), and SORT1 and b-actin (ACTB, D) in mouse ovaries. The expression of Ntsr1 (E) and Sort1 (F) in granulosa cells collected across the periovulatory period is depicted. Results are the means ± SEM. N = 4. Bars that do not share a letter designation are significantly different (P < 0.05).

Regulation of hCG-induced Nts expression in mouse granulosa cells

To understand the regulatory mechanism underlying Nts expression, granulosa cells were treated in vitro with specific inhibitors of hCG-activated signaling pathways in the presence and absence of hCG. As shown in Figure 3, Nts mRNA levels were increased by hCG treatment. Concomitant treatment with hCG and H89 (a PKA inhibitor) or SB (p38MAPK inhibitor) suppressed the hCG-induced Nts expression (Figure 3). These results indicate that the PKA pathway and p38MAPK are involved in hCG-induced upregulation of Nts expression in mouse granulosa cells.

Figure 3.

Figure 3

Effect of inhibitors on the hCG-induced increase in Nts expression in mouse granulosa cells in vitro. Granulosa cells were preincubated for 1 h with the following signaling inhibitors of hCG: H89 (PKA inhibitor), SB (SB203580; p38 MAPK inhibitor), GF (GF109203x; PKC inhibitor), LY (LY294002; PI3K inhibitor), or PD (MKK/MEK inhibitor). Cells were then treated with or without hCG treatment (1 IU/mL) for 4 h. Results are the means ± SEM. N = 6. Bars that do not share a letter designation are significantly different (P < 0.05).

Next, to study the role of LH/hCG-induced paracrine mediators regulating Nts expression, granulosa cells were cultured with inhibitors of the major LH/hCG signaling pathways such as the progesterone, prostaglandin, and the epidermal growth-like factor (EGF) pathways in presence and absence of hCG. Nts mRNA expression was induced by hCG and this induction was partially blocked by the EGF receptor inhibitor AG1478 in granulosa cells (Figure 4). This implies that Nts expression is also regulated via EGF receptor signaling. Furthermore, P4 levels were unchanged in the culture media treated with above-mentioned inhibitors, however, as expected hCG treatment increased P4 levels (Supplementary Figure 1).

Figure 4.

Figure 4

Effect of hCG-induced signaling pathway inhibitors on the regulation of Nts expression in mouse granulosa cells in vitro. Inhibitors for the hCG signaling pathways were used to determine which signaling pathways are involved in the expression of Nts. Granulosa cells were preincubated for 1 h with the following hCG pathway inhibitors: AG (AG1478; EGF receptor inhibitor), RU (RU486; progesterone receptor antagonist), and NS (NS398; prostaglandin synthase 2 inhibitor). Cells were then treated with or without hCG treatment (1 IU/mL) for 4 h. Results are the means ± SEM. N = 7. Bars that do not share a letter designation are significantly different (P < 0.05).

Effect of Nts knockdown in mouse granulosa cells

To examine the potential role of NTS during the ovulatory period, gene knockdown in mouse granulosa cells with small interfering RNA was employed. As expected, hCG treatment induced Nts expression at both 4 h and 12 h in the granulosa cells transfected with si-NC (Figure 5). Strikingly, in the granulosa cells transfected with si-Nts and treated with hCG for 4 h and 12 h, we observed by qPCR that Nts mRNA levels were reduced 75% and 90%, respectively, compared to Nts mRNA levels in granulosa cells treated with si-NC and hCG (Figure 5). Furthermore, P4 levels were unchanged in the culture media treated with si-NC or si-Nts, however, as expected hCG treatment increased P4 levels (Supplementary Figure 2).

Figure 5.

Figure 5

Effect of Nts gene knockdown by siRNA targeting Nts in mouse granulosa cells. Cells were transfected with scrambled siRNA (control; si-NC) or siRNA targeting Nts (si-Nts). After 3 h of transfection, cells were treated with or without hCG (1 IU/mL) for another 4 h (A) and 12 h (B). The expression of Nts mRNA after Nts knockdown is shown. Results are the means ± SEM. N = 4. Bars that do not share a letter designation are significantly different (P < 0.05).

Then, to identify RNA transcripts impacted by Nts silencing an RNAseq approach was utilized. Total RNA samples isolated from three groups (si-NC-Ctrl, si-NC-hCG, si-Nts-hCG) at 4 h and 12 h post hCG were subjected to RNA-seq (n = 4). The complete dataset was submitted to the Gene Expression Omnibus (accession GSE210811). A total of 60 genes were listed to be differentially expressed genes (DEGs) among which 43 were decreased in si-Nts-hCG vs si-NC-hCG, whereas 17 genes were increased in si-Nts-hCG vs si-NC-hCG at 4 h based on a selection criteria logCPM > 0.05, and false discovery rate < 0.05 (Figure 6A and Supplementary Table 1). A heatmap showed similarity and repeatability in the gene expression of each treatment group and stark differences between treatments (Figure 6B). In addition, a total of 3961 genes were regulated by hCG treatment at 4 h. Of the DEGs 2291 were decreased and 1670 genes were increased, respectively in the si-NC-hCG vs si-NC-Ctrl at 4 h treatment groups (Supplementary Table 1).

Figure 6.

Figure 6

RNA-seq analysis using primary mouse granulosa cells transfected with si-NC or si-NTS and treated with or without hCG for 4 h. High-throughput RNA-seq analysis was performed using mouse granulosa cells obtained from four replicates (one replicate contains pooled granulosa cells from three mice). The cells were transfected with si-NC (negative control) or si-Nts (siRNA specific to mouse Nts) and treated with or without hCG (1 IU/mL) for 4 h. (A) Mean-difference (MD) plot displays gene-wise log2-fold changes against average expression values together with a plot of sample expression. Dots in red, gray, and blue represent genes that show an increase, no change, or a decrease in expression values by the knockdown of Nts with hCG treatment, respectively. Arrows point to select specific genes that are decreased by Nts silencing that were further analyzed. (B) The heatmap indicates the group difference of DEGs between si-NC-Ctrl (no treatment), si-NC-hCG, and si-NTS-hCG treated mouse granulosa cells and the repeatability within each group. Thresholds used in MD plot and heatmap were FDR < 0.05 to select DEGs between the groups.

We next examined genes that were regulated by hCG treatment at 12 h. A total of 3521 genes were listed to be differentially expressed. Among 3521 DEGs,1722 genes were decreased and 1799 genes were increased, respectively in the si-NC-hCG vs si-NC-Ctrl treatment groups at 12 h based on a selection criteria logCPM > 0.05, and false discovery rate < 0.05 (Supplementary Table 2). Then, we examined the genes differentially regulated by silencing Nts. With the same selection criteria in si-NTS-hCG vs si-NC-hCG at 12 h groups, 331 genes were listed to be differentially expressed in si-NTS-hCG vs si-NC-hCG, (Supplementary Table 2). Of the DEGs, 209 and 122 genes were decreased and increased, respectively, in siNTS-hCG compared with the siNC-hCG treatment (Figure 7A and Supplementary Table 2). A heatmap showed similarity and repeatability in the gene expression of each treatment group and stark differences between treatments (Figure 7B). Among the 209 DEGs, 39 genes that were downregulated in Nts silenced granulosa cells were found to be upregulated by hCG, implying that these genes could be regulated by NTS in mouse granulosa cells (Table 2). In addition, among the 122 DEGs that were upregulated in granulosa cells treated with si-NTS-hCG, 33 genes were suppressed by hCG treatment (Table 2). This demonstrates that genes suppressed by LH/hCG during ovulation are also regulated by NTS as knocking down Nts expression lead to increased expression of these genes.

Figure 7.

Figure 7

RNA-seq analysis using primary mouse granulosa cells transfected with si-NC or si-NTS and treated with or without hCG for 12 h. High-throughput RNA-seq analysis was performed using mouse granulosa cells obtained from four replicates (one replicate contains pooled granulosa cells from three mice). The cells were transfected with si-NC (negative control) or si-Nts (siRNA specific to mouse Nts) and treated with or without hCG (1 IU/mL) for 12 h. (A) Mean-difference (MD) plot displays gene-wise log2-fold changes against average expression values together with a plot of sample expression. Dots in red, gray, and blue represent genes that show an increase, no change, or a decrease in expression values by the knockdown of Nts with hCG treatment, respectively. Arrows point to select specific genes that are decreased by Nts silencing that were further analyzed. (B) The heatmap indicates the group difference of DEGs between si-NC-Ctrl (no treatment), si-NC-hCG, and si-NTS-hCG treated mouse granulosa cells and the repeatability within each group. Thresholds used in MD plot and heatmap were FDR < 0.05 to select DEGs between the groups.

Table 2.

List of differentially regulated genes by Nts knockdown in mouse granulosa cells

S.N. Gene ENTREZID Product logFC (differentially regulated genes by silencing Nts) logFC (differentially regulated by hCG treatment)
1 Nts 67405 Neurotensin −3.095 3.529
2 Rsad2 58185 Radical S-adenosyl methionine domain containing 2 −1.541 1.467
3 Vps37a 52348 Vacuolar protein sorting 37A −1.204 0.6323
4 Ell2 192657 Elongation factor for RNA polymerase II 2 −0.9541 0.7553
5 Ubxn2a 217379 UBX domain protein 2A −0.8576 0.3915
6 Rgs9 19739 Regulator of G-protein signaling 9, transcript variant 2 −0.8037 0.7638
7 Rtn4r 65079 Reticulon 4 receptor −0.7779 0.6655
8 Adrb2 11555 Adrenergic receptor, beta 2 −0.7762 1.481
9 Pdap1 231887 PDGFA associated protein 1, transcript variant 1 −0.7598 0.4641
10 Gpr20 239530 G protein-coupled receptor 20 −0.7294 0.6305
11 Usp12 22217 Ubiquitin specific peptidase 12 −0.7231 0.4879
12 Rgs17 56533 Regulator of G-protein signaling 17, transcript variant 2 −0.6979 1.077
13 Ccn4 22402 Cellular communication network factor 4, transcript variant 1 −0.6288 1.108
14 Clcn5 12728 Chloride channel, voltage-sensitive 5, transcript variant X6 −0.581 0.6205
15 Ddx19a 13680 DEAD box helicase 19a −0.5521 0.5259
16 Pag1 94212 Phosphoprotein associated with glycosphingolipid microdomains 1, transcript variant A −0.5279 0.6528
17 Klhl29 208439 Kelch-like 29 −0.5108 0.6688
18 Mrpl19 56284 Mitochondrial ribosomal protein L19 −0.47 0.4783
19 E2f2 242705 E2F transcription factor 2, transcript variant 2 −0.4693 1.032
20 Podxl 27205 Podocalyxin-like −0.4504 0.4518
21 Selenoi 28042 Selenoprotein I, transcript variant 1 −0.4253 0.7486
22 Sowahc 268301 Sosondowah ankyrin repeat domain family member C −0.4225 0.4111
23 Il6ra 16194 Interleukin 6 receptor, alpha, transcript variant 2 −0.3899 0.806
24 Actr2 66713 ARP2 actin-related protein 2, transcript variant 2 −0.3885 0.3328
25 Zfp983 73229 Zinc finger protein 983, transcript variant X1 −0.3881 0.5492
26 Pdp2 382051 Pyruvate dehydrogenase phosphatase catalytic subunit 2 −0.3822 0.4902
27 Pank1 75735 Pantothenate kinase 1, transcript variant 1 −0.3797 0.2563
28 Wdr4 57773 WD repeat domain 4 −0.3719 0.3496
29 Tpcn1 252972 Two pore channel 1 −0.3671 0.356
30 Ankrd46 68839 Ankyrin repeat domain 46, transcript variant 3 −0.3472 0.6282
31 Slc6a6 21366 Solute carrier family 6 (neurotransmitter transporter, taurine), member 6 −0.3454 1.18
32 Cul2 71745 Cullin 2, transcript variant 2 −0.3231 0.3792
33 Layn 244864 Layilin, transcript variant X1 −0.3187 0.6605
34 Ttc9 69480 Tetratricopeptide repeat domain 9 −0.2934 1.039
35 Stx3 20908 Syntaxin 3, transcript variant A −0.2747 0.3696
36 Tmem87b 72477 Transmembrane protein 87B, transcript variant 2 −0.2411 0.2479
37 Stk38l 232533 Serine/threonine kinase 38 like, transcript variant 1 −0.2354 0.4117
38 Acadsb 66885 Acyl-Coenzyme A dehydrogenase, short/branched chain −0.2188 0.359
39 Brox 71678 BRO1 domain and CAAX motif containing, transcript variant 1 −0.1811 0.3339
40 Smtnl2 276829 Smoothelin-like 2 1.229 −2.759
41 Bend5 67621 BEN domain containing 5, transcript variant 1 0.7233 −1.076
42 Sox13 20668 SRY (sex determining region Y)-box 13, transcript variant X5 0.7226 −1.174
43 Ptprr 19279 Protein tyrosine phosphatase, receptor type, R, transcript variant 3 0.7213 −2.253
44 Rims1 116837 Regulating synaptic membrane exocytosis 1, transcript variant 5 0.7154 −1.432
45 Sox18 20672 SRY (sex determining region Y)-box 18 0.6962 −1.331
46 Cpox 12892 Coproporphyrinogen oxidase 0.6795 −0.3989

(continue)

We next examined a select few of these downregulated genes to confirm the RNAseq findings. As shown in Figure 8A–C, the expression of elongation factor for RNA polymerase II 2 (Ell2), radical S-adenosyl methionine domain containing 2 (Rsad2), and vacuolar protein sorting 37A (Vps37a), respectively, were confirmed by qPCR to be induced by hCG treatment and strongly decreased by knocking down Nts expression. In addition, smoothelin-like 2 (Smtnl2) was reduced by hCG treatment and strongly increased by knocking down Nts expression (Figure 8D). These qPCR data thereby confirm the RNAseq results. In addition, expression of prostaglandin synthase 2 (Ptgs2) and progesterone receptor (Pgr) were unchanged in Nts silenced cells (Figure 8E and F), implying that these two major LH-induced paracrine factors are not regulated by NTS.

Figure 8.

Figure 8

Effect of Nts gene knockdown in mouse granulosa cells. Cells were transfected with scrambled siRNA (si-NC) or siRNA targeting Nts (si-Nts). After 3 h of transfection, cells were treated with or without hCG (1 IU/mL) for another 12 h. The expression of (A) Ell2 mRNA, (B) Rsad2 mRNA, (C) Vps37a mRNA, (D) Smtnl2 mRNA, (E) Ptgs2 mRNA, and (F) Pgr mRNA after Nts knockdown is shown. Results are the means ± SEM. N = 4. Bars that do not share a letter designation are significantly different (P < 0.05).

Effect of Nts knockdown on mouse granulosa cell metabolism

To determine whether the knock-down of Nts expression in mouse granulosa cells resulted in any functional changes, cell metabolic activity was assessed. Cells were transfected with siNC as a control or si-Nts to knockdown Nts expression and then treated with or without hCG (1 IU/ml). The metabolic activity of granulosa cells was evaluated using the MTS assay. As shown in Figure 9, MTS values were increased by knocking down Nts expression alone. As expected, hCG treatment increased the MTS values, however hCG treatment masked the effect of Nts knockdown (Figure 9). This demonstrates that NTS may inversely regulate cell metabolic activity.

Figure 9.

Figure 9

Effect of Nts gene knockdown on mouse granulosa cell metabolic changes. Cells were transfected with scrambled siRNA (si-NC) or siRNA targeting Nts (si-Nts). After 3 h of transfection, cells were treated with or without hCG (1 IU/mL) for 24 h. Cell metabolic activity was assessed by recording the absorbance at 490 nm using the MTS assay. The experiments were repeated in four independent batches with three replicates in each batch. Results are the means ± SEM. N = 4. Bars that do not share a letter designation are significantly different (P < 0.05).

Discussion

The present findings characterize the induction, regulation, and function of NTS during the periovulatory period in the mouse ovary. The hCG-induced expression of Nts is robust in granulosa cells. This Nts expression is regulated through classical hCG signaling pathways acting, in part, through the EGF receptor signaling pathway. The receptors for NTS show different patterns of mRNA expression with only Sort1 decreasing after hCG. However, the protein levels of NTSR1 and SORT1 remained unchanged across the periovulatory period. Using a siRNA approach in combination with RNAseq, several genes such as Ell2, Rsad2, Vps37a, and Smtnl2 were identified as downstream genes of NTS. Moreover, knocking down Nts lead to increased cell metabolic activity implying that NTS could be acting as regulator of granulosa cell activity. These data provide new insight into the potential role of NTS during the periovulatory period.

In the current study, there is a rapid increase in Nts in granulosa cells within 4 h after hCG administration. These findings are similar to previous studies reporting a striking hCG-induced NTS mRNA expression in rat, human, and non-human primate granulosa cells [2, 3]. Furthermore, as demonstrated by immunolocalization of NTS in the both the human and non-human primate, hCG also induced NTS protein in granulosa cells [2, 3]. These studies establish that administration of hCG in vivo, to mimic the ovulatory LH surge, results in Nts stimulation in granulosa cells across the mouse, rat, non-human primate, and the human ovary. In addition, hCG-induced Nts expression was found to be regulated similarly across these species. In the present study, Nts mRNA is induced by hCG through the classical signaling pathways such as the PKA and p38MAPK pathways in mouse granulosa cells. Likewise, in the human and rat, hCG-induced NTS expression through the PKA, PKC, and MAPK signaling pathways [2]. There are, however, slight species differences in the hCG-induced Nts expression in granulosa cells. In the rat, PI3 kinase and MEK1/2 ERK1/2 signaling pathways were also shown to regulate hCG-induced Nts expression in granulosa cells [2]. Nonetheless, hCG induces Nts expression in granulosa cells via the cAMP-dependent PKA pathway which appears to be a major common signaling pathway in the mouse, rat, and human ovary.

Table 2.

Continued.

S.N. Gene ENTREZID Product logFC (differentially regulated genes by silencing Nts) logFC (differentially regulated by hCG treatment)
47 Tmem143 70209 Transmembrane protein 143 0.6704 −0.4108
48 Dlc1 50768 Deleted in liver cancer 1, transcript variant 2 0.6351 −0.7031
49 Ssx2ip 99167 Synovial sarcoma, X 2 interacting protein, transcript variant 1 0.6343 −0.682
50 Fos 14281 FBJ osteosarcoma oncogene 0.5989 −0.4406
51 Phlda1 21664 Pleckstrin homology like domain, family A, member 1 0.5458 −1.19
52 Tcim 69068 21 0.5347 −0.5192
53 Traf5 22033 TNF receptor-associated factor 5 0.5276 −1.131
54 Igsf9 93,842 Immunoglobulin superfamily, member 9, transcript variant 2 0.5177 −1.16
55 Rcan2 53901 Regulator of calcineurin 2, transcript variant 1 0.5102 −2.087
56 Tnfrsf21 94185 Tumor necrosis factor receptor superfamily, member 21 0.4713 −0.5271
57 Msrb3 320183 Methionine sulfoxide reductase B3 0.4608 −1.493
58 Sh3bp4 98402 SH3 domain-binding protein 4 0.4512 −0.7327
59 Prkacb 18749 Protein kinase, cAMP dependent, catalytic, beta, transcript variant 1 0.3677 −0.3108
60 Rhobtb3 73296 Rho-related BTB domain containing 3 0.3559 −0.6639
61 Lpcat1 210992 Lysophosphatidylcholine acyltransferase 1, transcript variant 1 0.3524 −0.2755
62 Fam122b 78755 Family with sequence similarity 122, member B, transcript variant X6 0.334 −0.6991
63 Egr1 13653 Early growth response 1 0.3185 −0.3997
64 Cited2 17684 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 0.3171 −0.4228
65 Pawr 114774 PRKC, apoptosis, WT1, regulator, transcript variant X1 0.3146 −0.4884
66 Rbpms 19663 RNA-binding protein gene with multiple splicing, transcript variant 2 0.2992 −0.6444
67 Fbxo21 231670 F-box protein 21, transcript variant 2 0.2959 −0.445
68 Rbpj 19664 Recombination signal binding protein for immunoglobulin kappa J region, transcript variant 2 0.275 −0.5301
69 Iqcb1 320299 IQ calmodulin-binding motif containing 1 0.2639 −0.4641
70 Mex3d 237400 mex3 RNA-binding family member D 0.2438 −0.3742
71 Fgfrl1 116701 Fibroblast growth factor receptor-like 1, transcript variant 1 0.2298 −0.6631
72 Dbn1 56320 Drebrin 1, transcript variant 3 0.2239 −0.7216
Legend       hCG-upregulated genes whose mRNA levels are reduced by NTS silencing
      hCG-downregulated genes whose mRNA levels are increased by NTS silencing

Another major LH/hCG-induced paracrine signaling pathway regulating NTS expression in the granulosa cells appears to be the EGF receptor signaling pathway [19]. Inhibition of the EGF signaling pathway results in a partial decrease in NTS mRNA in mouse granulosa cells in the present study which is similar to previous findings in the rat and human [2]. Likewise, in mouse cumulus cells EGF upregulated Nts mRNA levels and inhibition of MAPK kinase by using U0126 decreased the EGF-induced Nts expression [8]. The current findings in the mouse align with previous studies that have demonstrated an EGF regulation of NTS expression.

NTS conveys its action through its three receptors characterized as NTSR1, NTSR2, and SORT1 [14, 29]. In this study, the expression of Ntsr1 and Ntsr2 were extremely low and did not change with hCG treatment. Moreover, Ntsr2 was barely detectable in the mouse ovary and in granulosa cells. This expression pattern is similar to findings in human and monkey granulosa cells where expression of NTSR1 and NTSR2 mRNA was extremely low in the human [2] and in the monkey, NTSR2 was low while NTSR1 mRNA was undetectable [3]. However, there were species differences in the hCG-induced regulation of NTSR1 and NTSR2. In human granulosa cells collected across the periovulatory period, NTSR2 decreased approximately 80% after hCG administration during the preovulatory period [2], whereas NTSR2 was unchanged in monkey granulosa cells [3]. Unlike NTSR1 and NTSR2, the expression of SORT1 was abundant in mouse granulosa cells in the present study and in rat and human granulosa cells [2]. Although species differences were noted in the hCG regulation of SORT1 [3], in all species SORT1 was found to be the only NTS receptor mRNA that is highly expressed in granulosa cells even though the protein levels were unchanged. However, the role of the NTSR1 and NTSR2 in NTS action cannot be underestimated even though their mRNA expression levels were low in the granulosa cells. For example, NTSR1 and SORT1 are the prominent NTS receptors reported in certain cancers, such as pancreatic cancer and human colorectal cancer [30, 31], suggesting that these receptors could act as potential progressive biomarkers or pharmacological targets for novel therapies targeting the neurotensinergic pathways. A study of ovarian cancer cells showed that blockade of NTSR1 with an antagonist reduced cell proliferation but increased cell migration, whereas knockdown of SORT1 mimicked the anti-proliferative effects of NTSR1 blockade on ovarian cancer cells [12]. Thus, information derived from cancer studies implies that the type of receptor may dictate NTS actions and that some of these actions of NTS, such as cell proliferation and/or cell migration, may have a role in the ovulatory process.

In the present study, a Nts silencing approach followed by RNAseq has revealed several genes that are regulated by NTS. Genes such as Ell2, Rsad2, Vps37a, and Smtnl2 were found to be downstream of NTS in mouse granulosa cells. ELL2 is a member of the elongation factor component which is required to increase the catalytic rate of RNA polymerase II transcription [32, 33]. Studies using Ell2-knockout mice have revealed that the loss of Ell2 results in increased epithelial proliferation and vascularity in the prostate [34] and a reduction in Ig secretion and an alteration in the expression of the unfolded protein response genes in B cells [32]. Even though the role of ELL2 in the ovary is still unknown, it is possible that in the ovary ELL2 acts as in other systems to regulate cell proliferation, vascularity, and secretion of paracrine factors, all the key attributes that promote the ovulatory process.

Radical S-adenosylmethionine domain-containing protein 2 (RSAD2; viperin) is an interferon-inducible antiviral protein which plays a major role in the cell antiviral state. RSAD2 is a key enzyme in innate immune responses and inflammatory stimuli in many cell types [35]. A recent study has shown that decreased expression of interferon-stimulated genes occurs correspondingly with the decline of antiviral innate responsiveness in the later phase of SARS-CoV-2 infection [36]. Studies have highlighted the potential impact of SARS-CoV-2 in the ovary [37–39]. It was shown that in immortalized granulosa cells (COV434) stimulated with follicular fluid obtained from post COVID-19 patients, the expression of steroidogenic acute regulatory protein (StAR), estrogen-receptor β (Erβ), and vascular endothelial growth factor (VEGF) were significantly decreased, suggesting that SARS-CoV-2 infection adversely affects the follicular microenvironment [38]. Thus, stimulation of RASD2 either by LH or LH-induced NTS may have a protective effect against viral infection in the ovary. Moreover, in the ovary, RSAD2 induction in granulosa cells might be a self-defense mechanism to protect against viral entry into the follicle.

Vacuolar protein sorting 37 homolog A (VPS37A) is a member of the endosomal sorting complex required for the transport system involved in endocytosis [40]. Studies have demonstrated that silencing or knocking down VPS37A strongly delayed the degradation process of EGF receptor [40] and retained phosphorylated EFG receptor and hyperactivation of downstream EGF pathways [41]. These studies suggest a potential role of VPS37A in the follicle where VPS37A adjusts the signaling mechanism of paracrine factors, such as EGF signaling pathway, and might facilitate the transition of the ovulated follicle into the corpus luteum. In accord, cell metabolic activity was upregulated in Nts knocked down granulosa cells in the present study. In support, gene ontology analysis has shown that 68 genes involved in cellular metabolic process were influenced by Nts knockdown. Moreover, 56 genes involved in cellular macromolecule metabolic process were also affected by knocking down Nts. Nonetheless, studies on these genes require further research in the future. This suggests that NTS could inversely regulate cell activity supporting smooth transition of follicular cells to luteal cells.

Smoothelin-like 2 is a c-Jun N-terminal kinase substrate and acts as an actin filament-binding protein. It is expressed in skeletal muscle and is associated with differentiating myocytes [42]. Besides skeletal muscle cells, Sertoli cells in the mouse testis express Smtnl2 [43]. Knocking down Smtnl2 expression disrupted spermatogenesis and the blood-testis barrier [43]. The present study shows that Smtnl2 is expressed in mouse granulosa cells and the lack of Nts expression increased Smtnl2 expression. This implies that reduced Smtnl2 expression by NTS could regulate ovarian blood flow, thus facilitating follicle rupture.

In summary, these findings reveal that hCG-induced Nts regulates several novel genes that could potentially impact the ovulatory process thereby promoting ovulation and corpus luteum formation.

Authors’ contributions

KS: designed study, performed research, analyzed data, and wrote the paper. LAA: performed research, and analyzed data. PG: performed research, and analyzed data. MW: performed research, and analyzed data. PRH: analyzed data and wrote the paper. MJ: designed study, analyzed data, and wrote the paper. JD: analyzed data. DMD: designed study, analyzed data, and wrote the paper. TEC: designed study, performed research, analyzed data, and wrote the paper.

Data availability

The data underlying this article are available in Gene Expression Omnibus (GEO) database. The accession number is GSE210811.

Conflict of interest

The authors have declared that no conflict of interest exists.

Supplementary Material

Supplementary_Fig_1_ioac191
Supplementary_Fig_2_ioac191
Sup_Table_1_of_DEGs_from_NTS_silencing_and_hCG_treat_4h_ioac191
Sup_Table_2_of_DEGs_from_NTS_silencing_and_hCG_treat_12h_ioac191

Contributor Information

Ketan Shrestha, Department of Obstetrics & Gynecology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Linah Al-Alem, Department of Obstetrics & Gynecology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Priscilla Garcia, Department of Obstetrics & Gynecology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Michelle A A Wynn, Department of Obstetrics & Gynecology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Patrick R Hannon, Department of Obstetrics & Gynecology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Misung Jo, Department of Obstetrics & Gynecology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Jenny Drnevich, Roy J Carver Biotechnology Center, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.

Diane M Duffy, Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Virginia, USA.

Thomas E Curry Jr, Department of Obstetrics & Gynecology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

References

  • 1. Peng  XR, Hsueh  AJW, Lapolt  PS, Bjersing  L, Ny  T. Localization of luteinizing hormone receptor messenger ribonucleic acid expression in ovarian cell types during follicle development and ovulation. Endocrinology  1991; 129:3200–3207. [DOI] [PubMed] [Google Scholar]
  • 2. al-Alem  L, Puttabyatappa  M, Shrestha  K, Choi  Y, Rosewell  K, Brännström  M, Akin  J, Jo  M, Duffy  DM, Curry  TE  Jr. Neurotensin: a neuropeptide induced by hCG in the human and rat ovary during the periovulatory period. Biol Reprod  2021; 104:1337–1346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Campbell  GE, Bender  HR, Parker  GA, Curry te Jr, Duffy  DM. Neurotensin: a novel mediator of ovulation?  FASEB J  2021; 35:e21481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Kalafatakis  K, Triantafyllou  K. Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function. Regul Pept  2011; 170:7–17. [DOI] [PubMed] [Google Scholar]
  • 5. Li  J, Song  J, Zaytseva  YY, Liu  Y, Rychahou  P, Jiang  K, Starr  ME, Kim  JT, Harris  JW, Yiannikouris  FB, Katz  WS, Nilsson  PM  et al.  An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature  2016; 533:411–415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Osadchii  OE. Emerging role of neurotensin in regulation of the cardiovascular system. Eur J Pharmacol  2015; 762:184–192. [DOI] [PubMed] [Google Scholar]
  • 7. Wissing  ML, Kristensen  SG, Andersen  CY, Mikkelsen  AL, Høst  T, Borup  R, Grøndahl  ML. Identification of new ovulation-related genes in humans by comparing the transcriptome of granulosa cells before and after ovulation triggering in the same controlled ovarian stimulation cycle. Hum Reprod  2014; 29:997–1010. [DOI] [PubMed] [Google Scholar]
  • 8. Hiradate  Y, Inoue  H, Kobayashi  N, Shirakata  Y, Suzuki  Y, Gotoh  A, Roh  SG, Uchida  T, Katoh  K, Yoshida  M, Sato  E, Tanemura  K. Neurotensin enhances sperm capacitation and acrosome reaction in mice. Biol Reprod  2014; 91:53. [DOI] [PubMed] [Google Scholar]
  • 9. Dias  FC, Khan  MIR, Sirard  MA, Adams  GP, Singh  J. Differential gene expression of granulosa cells after ovarian superstimulation in beef cattle. Reproduction  2013; 146:181–191. [DOI] [PubMed] [Google Scholar]
  • 10. Vincent  JP, Mazella  J, Kitabgi  P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci  1999; 20:302–309. [DOI] [PubMed] [Google Scholar]
  • 11. Mazella  J. Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking?  Cell Signal  2001; 13:1–6. [DOI] [PubMed] [Google Scholar]
  • 12. Norris  EJ, Zhang  Q, Jones  WD, DeStephanis  D, Sutker  AP, Livasy  CA, Ganapathi  RN, Tait  DL, Ganapathi  MK. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. J Pathol  2019; 248:352–362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Martin  S, Vincent  JP, Mazella  J. Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia. J Neurosci  2003; 23:1198–1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Kleczkowska  P, Lipkowski  AW. Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation--a review. Eur J Pharmacol  2013; 716:54–60. [DOI] [PubMed] [Google Scholar]
  • 15. Kim  JT, Napier  DL, Weiss  HL, Lee  EY, Townsend  CM  Jr, Evers  BM. Neurotensin receptor 3/sortilin contributes to tumorigenesis of neuroendocrine tumors through augmentation of cell adhesion and migration. Neoplasia  2018; 20:175–181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Akter  H, Park  M, Kwon  OS, Song  EJ, Park  WS, Kang  MJ. Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol  2015; 36:6053–6062. [DOI] [PubMed] [Google Scholar]
  • 17. Béraud-Dufour  S, Coppola  T, Massa  F, Mazella  J. Neurotensin receptor-2 and -3 are crucial for the anti-apoptotic effect of neurotensin on pancreatic beta-TC3 cells. Int J Biochem Cell Biol  2009; 41:2398–2402. [DOI] [PubMed] [Google Scholar]
  • 18. Zhang  Y, Zhu  S, Yi  L, Liu  Y, Cui  H. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells. Mol Cell Biochem  2014; 389:1–8. [DOI] [PubMed] [Google Scholar]
  • 19. Choi  Y, Wilson  K, Hannon  PR, Rosewell  KL, Brännström  M, Akin  JW, Curry  TE  Jr, Jo  M. Coordinated regulation among progesterone, prostaglandins, and EGF-like factors in human ovulatory follicles. J Clin Endocrinol Metab  2017; 102:1971–1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Jo  M, Curry  TE  Jr. Luteinizing hormone-induced RUNX1 regulates the expression of genes in granulosa cells of rat periovulatory follicles. Mol Endocrinol  2006; 20:2156–2172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Hannon  PR, Duffy  DM, Rosewell  KL, Brännström  M, Akin  JW, Curry  TE  Jr. Ovulatory induction of SCG2 in human, nonhuman primate, and rodent granulosa cells stimulates ovarian angiogenesis. Endocrinology  2018; 159:2447–2458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Patro  R, Duggal  G, Love  MI, Irizarry  RA, Kingsford  C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods  2017; 14:417–419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Soneson  C, Love  MI, Robinson  MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res  2015; 4:1521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. McCarthy  DJ, Chen  Y, Smyth  GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res  2012; 40:4288–4297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Chen  Y, Lun  AT, Smyth  GK. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Res  2016; 5:1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. RRID:AB_10989085. https://antibodyregistry.org/ search.php?q=AB_10989085.
  • 27. RRID:AB_2192606. https://antibodyregistry.org/search?q=AB_2192606.
  • 28. RRID:AB_2223172. https://antibodyregistry.org/search.php?q=AB_2223172
  • 29. Ouyang  Q, Zhou  J, Yang  W, Cui  H, Xu  M, Yi  L. Oncogenic role of neurotensin and neurotensin receptors in various cancers. Clin Exp Pharmacol Physiol  2017; 44:841–846. [DOI] [PubMed] [Google Scholar]
  • 30. Takahashi  K, Ehata  S, Miyauchi  K, Morishita  Y, Miyazawa  K, Miyazono  K. Neurotensin receptor 1 signaling promotes pancreatic cancer progression. Mol Oncol  2021; 15:151–166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Wu  Z, Martinez-Fong  D, Trédaniel  J, Forgez  P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol (Lausanne)  2012; 3:184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Park  KS, Bayles  I, Szlachta-McGinn  A, Paul  J, Boiko  J, Santos  P, Liu  J, Wang  Z, Borghesi  L, Milcarek  C. Transcription elongation factor ELL2 drives Ig secretory-specific mRNA production and the unfolded protein response. J Immunol  2014; 193:4663–4674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ghobrial  A, Flick  N, Daly  R, Hoffman  M, Milcarek  C. ELL2 influences transcription elongation, splicing, Ig secretion and growth. J Mucosal Immunol Res  2019; 3. PMID: 31930204. [PMC free article] [PubMed] [Google Scholar]
  • 34. Pascal  LE, Masoodi  KZ, Liu  J, Qiu  X, Song  Q, Wang  Y, Zang  Y, Yang  T, Wang  Y, Rigatti  LH, Chandran  U, Colli  LM  et al.  Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol  2017; 235:123–136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Seo  JY, Yaneva  R, Cresswell  P. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe  2011; 10:534–539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Seeßle  J, Hippchen  T, Schnitzler  P, Gsenger  J, Giese  T, Merle  U. High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: immunological findings. PLoS One  2021; 16:e0254129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Russo  C, Morello  G, Malaguarnera  R, Piro  S, Furno  DL, Malaguarnera  L. Candidate genes of SARS-CoV-2 gender susceptibility. Sci Rep  2021; 11:21968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Herrero  Y, Pascuali  N, Velázquez  C, Oubiña  G, Hauk  V, de Zúñiga  I, Peña  MG, Martínez  G, Lavolpe  M, Veiga  F, Neuspiller  F, Abramovich  D  et al.  SARS-CoV-2 infection negatively affects ovarian function in ART patients. Biochim Biophys Acta Mol Basis Dis  2022; 1868:166295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Choi  Y, Jeon  H, Brännström  M, Akin  JW, Curry  TE  Jr, Jo  M. Ovulatory upregulation of angiotensin-converting enzyme 2, a receptor for SARS-CoV-2, in dominant follicles of the human ovary. Fertil Steril  2021; 116:1631–1640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Bache  KG, Slagsvold  T, Cabezas  A, Rosendal  KR, Raiborg  C, Stenmark  H. The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation. Mol Biol Cell  2004; 15:4337–4346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Wittinger  M, Vanhara  P, el-Gazzar  A, Savarese-Brenner  B, Pils  D, Anees  M, Grunt  TW, Sibilia  M, Holcmann  M, Horvat  R, Schemper  M, Zeillinger  R  et al.  hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer. Clin Cancer Res  2011; 17:7816–7827. [DOI] [PubMed] [Google Scholar]
  • 42. Gordon  EA, Whisenant  TC, Zeller  M, Kaake  RM, Gordon  WM, Krotee  P, Patel  V, Huang  L, Baldi  P, Bardwell  L. Combining docking site and phosphosite predictions to find new substrates: identification of smoothelin-like-2 (SMTNL2) as a c-Jun N-terminal kinase (JNK) substrate. Cell Signal  2013; 25:2518–2529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Wu  D, Zhang  K, Khan  FA, Pandupuspitasari  NS, Liang  W, Huang  C, Sun  F. Smtnl2 regulates apoptotic germ cell clearance and lactate metabolism in mouse Sertoli cells. Mol Cell Endocrinol  2022; 551:111664. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary_Fig_1_ioac191
Supplementary_Fig_2_ioac191
Sup_Table_1_of_DEGs_from_NTS_silencing_and_hCG_treat_4h_ioac191
Sup_Table_2_of_DEGs_from_NTS_silencing_and_hCG_treat_12h_ioac191

Data Availability Statement

The data underlying this article are available in Gene Expression Omnibus (GEO) database. The accession number is GSE210811.


Articles from Biology of Reproduction are provided here courtesy of Oxford University Press

RESOURCES